Advanced Search
HAN Zhi-gang, SHAN Li, LIU Chun-ling. Expression of the Serum GST-π Level in Patients with Advanced NSCLC and Its Clinical Significance[J]. Cancer Research on Prevention and Treatment, 2007, 34(05): 336-339. DOI: 10.3971/j.issn.1000-8578.1706
Citation: HAN Zhi-gang, SHAN Li, LIU Chun-ling. Expression of the Serum GST-π Level in Patients with Advanced NSCLC and Its Clinical Significance[J]. Cancer Research on Prevention and Treatment, 2007, 34(05): 336-339. DOI: 10.3971/j.issn.1000-8578.1706

Expression of the Serum GST-π Level in Patients with Advanced NSCLC and Its Clinical Significance

More Information
  • Corresponding author:

    SHAN Li

  • Received Date: March 29, 2006
  • Revised Date: July 24, 2006
  • Objective  To detect the expression of serum glutathione S-t ransferase-π ( GST-π) level in patients with NSCLC, and to investigate it s clinical significance. Methods  GST-π levels in serum of 46 patients with NSCLC, 19 patients with benign lung diseases and 60 health subjects were detected with ELISA. Forty-six NSCLC patients were given 2 cycles of NVB + DDP chemotherapy and clinical response was evaluated. Results  The mean serum GST-π level was significantly higher in patient s with NSCLC than in those with benign lung disease and health subject s ( P < 0. 05) . Twenty-five of 46 patients with NSCLC (54. 34 %) showed elevated serum GST-π levels above a cutoff value of 166. 14 ng/ml (mean +two standard deviations in 60 healthy control subjects) . The positive rate was significantly higher in patients with NSCLC than in those with benign lung disease 36. 84 % and heavy subjects 3. 33 % ( P <0. 05) . The positive rate of serum GST-π were 57. 14 % in squamous cell carcinoma and 52. 00 % in adenocarcinoma ( P > 0. 05) . No correlation was observed between the GST-πlevel and stage, sex, pathohistology. Of the 46 patient s treated with NVB + DDP chemotherapy, 19 patients responded to chemotherapy (overall response rate, 41. 30 %) . For the 25 patients with positive GST-πexpression, 5 patients responded to chemotherapy, response rate was 20 %. In the 21 patient s with negative GST-πexpression, 14 patients responded to chemotherapy, respone rate was 66. 67 %. This difference was statistically significant ( P < 0. 05) . Conclusion  The serum GST-π level may be a valuable tumor marker for NSCLC, There was no correlation between expression of serum GST-π and stage, sex, pathohistology. The response rate of NSCLC patients with GST-π-negative expression was higher than those with GST-π-positive. GST-2π may be a useful predictor of chemotherapy response.
  • Related Articles

    [1]FENG Qian, LIU Xian, ZHANG Ni, CUI Nan. HK2 Promotes Proliferation and Migration of Cervical Cancer Cells by Up-regulating Cyclin D1 and MMP7 Expression Through Wnt/β-catenin Signaling Pathway[J]. Cancer Research on Prevention and Treatment, 2020, 47(9): 649-654. DOI: 10.3971/j.issn.1000-8578.2020.20.0094
    [2]HAN Xiang-chun, KANG Jin-wang, ZHENG Li-qiang, ZUO Lian-fu. Expression of Wnt1,β-catenin,PC and cyclinD1 Proteins in Gastric Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(02): 163-166. DOI: 10.3971/j.issn.1000-8578.2011.02.012
    [3]XIONG Yan, XIONG Yong-yan. Expression and Significance of p16,Cyclin D1 and COX-2 Proteinin VariousHyperplasticLesions of Endometrium[J]. Cancer Research on Prevention and Treatment, 2010, 37(05): 551-554. DOI: 10.3971/j.issn.1000-8578.2010.05.017
    [4]XIAO Jing, LIU Shao-yang, JIANG Da-qiong. Expressions of p57kip2 and cyclin D1 Proteins in Epithelial Ovarian Carcinoma and Their Clinical Significance[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 330-332. DOI: 10.3971/j.issn.1000-8578.2010.03.024
    [5]ZHAO Ya-juan, YIN Fei. Expression of ERK-1 and Cyclin D1 in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 175-180. DOI: 10.3971/j.issn.1000-8578.2010.02.014
    [6]ZHOU Zheng-ping, XIAO Qing-bang, RAN Feng-feng, WANG Jin-jing, ZHENG Hong. Expression of p57 KIP2, cyclin D1, and cycl in Eand Their Clinical Significances in Squamous Cell Carcinoma of Uterine Cervix[J]. Cancer Research on Prevention and Treatment, 2007, 34(07): 511-513. DOI: 10.3971/j.issn.1000-8578.2760
    [7]HU Ji-jun, FANG Xiang-ming, XIONG Bi-fang, PENG Bo, TIAN Xia, LONG Yan-hua. Expression and Clinical Pathology of eIF4E and cyclin D1 in Gastric Carcinoma[J]. Cancer Research on Prevention and Treatment, 2006, 31(02): 97-99,封. DOI: 10.3971/j.issn.1000-8578.1044
    [8]LI Ai bin, WANG Qiong shu, LIU Yuan jiao, SHI Yu xia. K-ras and MTS1/p16 Gene Expression in Endometrial Carcinoma and Benign Endometrium and its Significance[J]. Cancer Research on Prevention and Treatment, 2004, 31(07): 406-408. DOI: 10.3971/j.issn.1000-8578.269
    [9]SI Xiao-hui, YANG Lian-jun, LIU Zheng. Expression of cyclin D1 and cdk4 in chondrosarcoma of the jaws[J]. Cancer Research on Prevention and Treatment, 2002, 29(03): 200-202. DOI: 10.3971/j.issn.1000-8578.3228
    [10]SU Guo-qiang, MAO Qian-guo, ZAO Wei-xing, et al, . Express ion of nm23-H1 Gene and ras Gene and Their Relations to Lymph Node Metastasis in Human Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(05): 354-355. DOI: 10.3971/j.issn.1000-8578.1354

Catalog

    Article views (2238) PDF downloads (559) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return